Spero Therapeutics Files 8-K on Financials
Ticker: SPRO · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Spero Therapeutics dropped its 8-K on March 13, 2024, with financial updates.
AI Summary
On March 13, 2024, Spero Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, providing an update on the company's fiscal performance.
Why It Matters
This filing provides investors with an update on Spero Therapeutics' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- 0001193125-24-066825 (filing_id) — Accession Number
- March 13, 2024 (date) — Date of Report
- 001-38266 (company_id) — SEC File Number
- 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Spero Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 13, 2024.
What is Spero Therapeutics, Inc.'s principal executive office address?
Spero Therapeutics, Inc.'s principal executive office is located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.
What is the SEC File Number for Spero Therapeutics, Inc.?
The SEC File Number for Spero Therapeutics, Inc. is 001-38266.
What is the Standard Industrial Classification code for Spero Therapeutics, Inc.?
The Standard Industrial Classification code for Spero Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-13 16:07:52
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
Filing Documents
- d809069d8k.htm (8-K) — 24KB
- d809069dex991.htm (EX-99.1) — 71KB
- 0001193125-24-066825.txt ( ) — 226KB
- spro-20240313.xsd (EX-101.SCH) — 3KB
- spro-20240313_lab.xml (EX-101.LAB) — 18KB
- spro-20240313_pre.xml (EX-101.PRE) — 11KB
- d809069d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release, dated March 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 13, 2024 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer and Chief Business Officer